Table 1. Multicenter trials of neoadjuvant imatinib therapy for GIST.

Ref.	Design	Endpoint	No. of patients	Dose (mg)	Duration	R0 resection rate (%)	Adjuvant imatinib	Survival outcome
Eisenberg et al. (5) 2009; Wang et al. (6) 2012	Phase II	RFS	31	600	8–10 weeks	68	24 months	2-yr RFS: 83.9%; 5-yr RFS: 56.7%
Blesius et al. (7) 2011	Subset analysis of phase III	–	9	400	4.2 months (median)	56	13–24 months	3-yr PFS: 67%; 3-yr OS: 89%
Doyon et al. (8) 2012	Phase II	Response rate	12	400	6 months	100	12 months	4-yr DFS: 100%; 4-yr OS: 64%
Hohenberger et al. (9) 2012	Phase II	Overall tumor response	41	400	6 months	88	Not planned	3-yr RFS: 85.2%
Tielen et al. (10) 2013	Database analysis	PFS	57	400	8 months (median)	84	1, 2 years or lifelong	5-yr PFS: 77%; 5-yr OS: 88%
Rutkowski et al. (11) 2013	Database analysis	–	161	400	40 weeks (median)	83	At least 1 year	5-yr DFS: 65%; 5-yr DSS: 95%
Kurokawa et al. (12) 2017	Phase II	PFS	53	400	6–9 months	91	36 months	2-yr PFS: 89%; 2-yr OS: 98%

RFS, recurrent free survival; PFS, progression free survival; OS, overall survival; DFS, disease free survival; DSS, disease specific survival.